Automated And Closed Cell Therapy Processing Systems Market Opportunities & Forecast 2022-2030

The global Automated And Closed Cell Therapy Processing Systems market size is expected to be worth around US$ 6.94 billion by 2030, according to a new report by Vision Research Reports.

The global Automated And Closed Cell Therapy Processing Systems market size was valued at US$ 715.0 million in 2020 and is anticipated to grow at a CAGR of 22.7% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38922

Report Coverage

Report Scope Details
Market Size US$ 6.94 Billion by 2030
Growth Rate CAGR of 22.7% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Workflow, Type, Scale
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned MiltenyiBiotec; Lonza; Fresenius Kabi; Cytiva (Danaher Corp.); BioSpherix, Ltd.; Terumo Corporation; Sartorius AG; ThermoGenesis Holdings, Inc.; Cellares, Inc.; Thermo Fisher Scientific, Inc.

Growth Factors

 The growing popularity of regenerative medicines & cell therapies coupled with a range of benefits offered by automation technologies for the development of these therapies is expected to propel the market growth. In addition, the growing integration of software technologies and advanced therapy development processes is also projected to boost the market. Furthermore, rising investments by bio manufacturers for the development of cellular therapy products through rounds of series funding are anticipated to offer lucrative opportunities to or the market.

The rapid growth in the cases of COVID-19 is anticipated to play a vital role in the market growth. The pandemic has led to an increased focus on automation technologies. Moreover, the companies emphasized raising funds with an aim to develop advanced therapies and regenerative medicines to fight against COVID-19. Industry players are also concentrating on the development of new therapies, such as stem cell therapy, natural killer cell therapy, exosomes, and others.

By Workflow Analysis

The expansion segment accounted for the largest revenue share of more than 35% in 2020. The growth is majorly attributed to the presence of a substantial number of products offered under this segment.

separation workflow is estimated to register the fastest CAGR during the forecast period. The cell separation process is carried out across various cellular experiments, such as molecular analysis, cellular genetic modification, production of hybridomas, and other cell research & analysis-related applications.

A growing number of research activities for these applications in academic universities and other research settings is anticipated to accelerate the segment growth. Apart from expansion and separation, the workflow segment comprises apheresis, fill-finish, cryopreservation, and others.

By Type Analysis

The non-stem cell therapy segment captured the maximum revenue share of over 61% in 2020 and is anticipated to register the fastest CAGR during the forecast period. An increasing number of product launches for non-stem cell therapy applications is expected to drive the segment growth.

Companies are extensively engaging in partnerships and collaboration with an aim to develop new regenerative medicines for the treatment of chronic conditions. Such research projects majorly focus on applications of non-stem cells, consequently driving the non-stem cell therapy segment growth.

The stem cell therapy segment is anticipated to witness a significant growth rate during the forecast period. Increasing awareness about therapeutic benefits offered by stem cell therapies and rising research activities.

By Scale Analysis

The pre-commercial/R&D scale segment dominated the global market in 2020 with a revenue share of more than 72%.At present, the market is relatively niche due to a limited number of products. Moreover, the majority of the companies are introducing their products only for research purposes.

the adoption of automated systems by research institutes due to the growing number of clinical trials for cell therapies is also projected to accelerate segment growth. The laboratories and research institutes are witnessing a range of benefits due to the adoption of automated systems.

The commercial-scale segment is expected to register the fastest CAGR from 2021 to 2028. The increasing prevalence of chronic conditions, such as cancer, is encouraging companies to develop enhanced cell-therapy-based therapeutic platforms.

By Regional Analysis

North America accounted for the largest revenue share of over 45.5%in 2020. This high share was majorly attributed to the increased technological adoption for cell therapy processing and emphasis on high precision & production throughput.

Growing investments by market players as well as research institutes are also expected to play a vital role in the region’s growth. Growing investments by market players as well as research institutes are also expected to play a vital role in the region’s growth.

Over the recent year, a series of fully automated platforms were introduced across European countries, which is capable of supporting the bioprocess workflows from start to end.

Key Players

  • MiltenyiBiotec
  • Lonza
  • Fresenius Kabi
  • Cytiva (Danaher Corp.)
  • BioSpherix, Ltd.
  • Terumo Corporation
  • Sartorius AG
  • ThermoGenesis Holdings, Inc.
  • Cellares Inc.
  • Thermo Fisher Scientific, Inc.

Market Segmentation

  • By Workflow
    • Separation
    • Expansion
    • Apheresis
    • Fill- Finish
    • Cryopreservation
    • Others
  • By Type
    • Stem Cell Therapy
    • Non-Stem Cell Therapy
  • By Scale
    • Pre-commercial/R&D Scale
    • Commercial Scale
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Spain
      • Italy
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38922

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Automated And Closed Cell Therapy Processing Systems Market, By Workflow

7.1.  Automated And Closed Cell Therapy Processing Systems Market, by Workflow, 2021-2030

7.1.1.    Separation

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Expansion

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Apheresis

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Fill- Finish

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    Cryopreservation

7.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Automated And Closed Cell Therapy Processing Systems Market, By Type

8.1.  Automated And Closed Cell Therapy Processing Systems Market, by Type, 2021-2030

8.1.1.    Stem Cell Therapy

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Non-Stem Cell Therapy

8.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Automated And Closed Cell Therapy Processing Systems Market, By Scale

9.1.  Automated And Closed Cell Therapy Processing Systems Market, by Scale, 2021-2030

9.1.1.    Pre-commercial/R&D Scale

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Commercial Scale

9.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Automated And Closed Cell Therapy Processing Systems Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Workflow (2017-2030)

10.1.2.  Market Revenue and Forecast, by Type (2017-2030)

10.1.3.  Market Revenue and Forecast, by Scale (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Workflow (2017-2030)

10.2.2.  Market Revenue and Forecast, by Type (2017-2030)

10.2.3.  Market Revenue and Forecast, by Scale (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Type (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Type (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Workflow (2017-2030)

10.3.2.  Market Revenue and Forecast, by Type (2017-2030)

10.3.3.  Market Revenue and Forecast, by Scale (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Type (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Type (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Workflow (2017-2030)

10.4.2.  Market Revenue and Forecast, by Type (2017-2030)

10.4.3.  Market Revenue and Forecast, by Scale (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Type (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Type (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Workflow (2017-2030)

10.5.2.  Market Revenue and Forecast, by Type (2017-2030)

10.5.3.  Market Revenue and Forecast, by Scale (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Type (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by Scale (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Workflow (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Type (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by Scale (2017-2030)

Chapter 11.  Company Profiles

11.1.              MiltenyiBiotec

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Lonza

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Fresenius Kabi

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Cytiva (Danaher Corp.)

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              BioSpherix, Ltd.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Terumo Corporation

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Sartorius AG

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              ThermoGenesis Holdings, Inc

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Cellares Inc.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Thermo Fisher Scientific, Inc.

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38922

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com